The DOI matches its Crossref record.
Inhibition of Allergic Reactions with Antibodies to IgE
Abstract
Numerous clinical studies show that direct interference with the IgE response leads to a decrease or elimination of allergic symptoms. The aim of these studies was to design a therapy aimed at decreasing IgE levels in order to ameliorate atopic disease. To this end, a murine monoclonal antibody, MAE11, directed against IgE was identified, which had all the properties necessary to interfere with IgE responses, but lacked the harmful side effects of inducing receptor cross-linking. The antibody was selected on the basis of its ability to bind circulating IgE at the same site as the high-affinity receptor, thus blocking the binding of IgE to mast cells and basophils. To allow for possible chronic administration and to avoid the problems of antigenicity, MAE11 was humanized. The best of several humanized variants, version 25 (rhumAb-E25) was selected since it possessed binding affinity and biological activity comparable to MAE11. Clinical studies are underway to determine the safety and efficacy of this treatment for allergic rhinitis and asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Mehlhop, P. D., van de Rijn, M., Goldberg, A. B., Brewer, J. P., Kurup, V. P., Martin, T. R., & Oettgen, H. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1344 · Cited by 368
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★
Casale, T. B., Bernstein, I. L., Busse, W. W., LaForce, C. F., Tinkelman, D. G., Stoltz, R. R., Dockhorn, R. J., Reimann, J., Su, J. Q., & Fick Jr., R. B. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70202-1 · Cited by 326
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S. (2017) · Allergy · doi:10.1111/all.13083 · Cited by 293
Rodrigo, G. J., Neffen, H., & Castro-Rodriguez, J. A. (2011) · Chest · doi:10.1378/chest.10-1194 · Cited by 268
Treatment of recalcitrant atopic dermatitis with omalizumab
Lane, J. E., Cheyney, J. M., Lane, T. N., Kent, D. E., & Cohen, D. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.09.030 · Cited by 188
HAAK‐FRENDSCHO, SABAN†, SHIELDS, & JARDIEU (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00478.x · Cited by 18
Metadata
- Authors
- Shields, R. L., Whether, W. R., Zioncheck, K., O’Connell, L., Fendly, B., Presta, L. G., Thomas, D., Saban, R., & Jardieu, P.
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 1995
- Volume
- 107
- Issue
- 1-3
- Pages
- 308-312
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2009376119
- Cited by
- 183
- References
- 0
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.